February 22, 2019

Deal Snapshot: Merck & Co and Immune Design

Median deal values by quarter

  • Deal Headline: Merck to Acquire Immune Design (21 Feb 2019)
  • Deal Type: Acquisition
  • Acquirer: Merck & Co
  • Target: Immune Design
  • Therapeutic Area: Immunology
  • Total Deal Size: USD 300M

Merck & Co Key BD Contacts

Merck & Co Deal Activity by Therapeutic Area (Last 3 Years)

Recent deal activity by disease area

Recent In-Licensing Deals and Acquisitions:

Merck & Co Pipeline Composition

Pipeline composition, disease areas

Merck & Co Lead Immunology Assets

Asset Indication Stage
MK-1654 Respiratory syncytial virus Phase II
MK-3641 Ragweed allergic rhinitis Phase III
MK-4117 Perennial allergic rhinitis Phase III

Business profiles tailored to your asset.